Homology Medicines, Inc. (0T6G.L)
USD 1.66
(9.57%)
USD 1.66
(9.57%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -53.74 Million USD | -973.79% |
| 2022 | -5 Million USD | 94.77% |
| 2021 | -95.76 Million USD | 25.59% |
| 2020 | -128.69 Million USD | -23.84% |
| 2019 | -103.91 Million USD | -86.98% |
| 2018 | -55.57 Million USD | -85.31% |
| 2017 | -29.99 Million USD | -272.7% |
| 2016 | -8.04 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.02 Million USD | 106.38% |
| 2024 Q2 | -16.97 Million USD | -1749.95% |
| 2023 Q3 | -32.95 Million USD | 5.96% |
| 2023 Q4 | -16.11 Million USD | 51.09% |
| 2023 Q1 | -28.84 Million USD | 15.89% |
| 2023 FY | -112.96 Million USD | -2156.96% |
| 2023 Q2 | -35.04 Million USD | -21.49% |
| 2022 Q1 | 92.1 Million USD | 374.26% |
| 2022 Q4 | -34.29 Million USD | -1.69% |
| 2022 Q2 | -29.08 Million USD | -131.58% |
| 2022 Q3 | -33.72 Million USD | -15.94% |
| 2022 FY | -5 Million USD | 94.77% |
| 2021 Q2 | -30.5 Million USD | -2742.5% |
| 2021 FY | -95.76 Million USD | 25.59% |
| 2021 Q1 | -1.07 Million USD | 96.4% |
| 2021 Q4 | -33.58 Million USD | -9.72% |
| 2021 Q3 | -30.6 Million USD | -0.35% |
| 2020 Q4 | -29.79 Million USD | -5.52% |
| 2020 FY | -128.69 Million USD | -23.84% |
| 2020 Q2 | -35.34 Million USD | -0.03% |
| 2020 Q1 | -35.33 Million USD | -46.2% |
| 2020 Q3 | -28.23 Million USD | 20.11% |
| 2019 Q3 | -29.62 Million USD | -12.78% |
| 2019 Q1 | -23.85 Million USD | -26.97% |
| 2019 FY | -103.91 Million USD | -86.98% |
| 2019 Q4 | -24.16 Million USD | 18.43% |
| 2019 Q2 | -26.27 Million USD | -10.14% |
| 2018 Q2 | -12.42 Million USD | -21.62% |
| 2018 Q4 | -18.78 Million USD | -32.78% |
| 2018 FY | -55.57 Million USD | -85.31% |
| 2018 Q1 | -10.21 Million USD | 14.19% |
| 2018 Q3 | -14.14 Million USD | -13.86% |
| 2017 Q1 | -5.55 Million USD | 0.0% |
| 2017 FY | -29.99 Million USD | -272.7% |
| 2017 Q3 | -6.52 Million USD | -8.74% |
| 2017 Q4 | -11.9 Million USD | -82.39% |
| 2017 Q2 | -6 Million USD | -8.06% |
| 2016 FY | -8.04 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 64.924% |
| Dynavax Technologies Corporation | -6.38 Million USD | -741.18% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 54.652% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.378% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 4183.815% |
| Perrigo Company plc | -12.7 Million USD | -323.173% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 80.537% |
| Illumina, Inc. | -1.16 Billion USD | 95.371% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.896% |
| Nektar Therapeutics | -276.05 Million USD | 80.532% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 87.897% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 103.958% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 51.39% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -34.829% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 132.058% |
| Waters Corporation | 642.23 Million USD | 108.368% |
| Biogen Inc. | 1.16 Billion USD | 104.629% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 79.156% |
| Adicet Bio, Inc. | -142.65 Million USD | 62.327% |
| Evolus, Inc. | -61.68 Million USD | 12.875% |
| bluebird bio, Inc. | -211.91 Million USD | 74.639% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 39.26% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 74.316% |
| FibroGen, Inc. | -284.23 Million USD | 81.092% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 104.334% |
| Geron Corporation | -184.12 Million USD | 70.812% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 87.792% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -20.491% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 64.546% |
| Myriad Genetics, Inc. | -112 Million USD | 52.015% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.359% |
| OPKO Health, Inc. | -188.86 Million USD | 71.544% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 37.432% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 88.831% |
| Zoetis Inc. | 2.34 Billion USD | 102.293% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 0.821% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 106.813% |
| Exelixis, Inc. | 207.76 Million USD | 125.867% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 101.485% |
| uniQure N.V. | -308.47 Million USD | 82.578% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -27.356% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -13.131% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 77.536% |
| Verastem, Inc. | -87.36 Million USD | 38.486% |
| Imunon, Inc. | -19.51 Million USD | -175.394% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 85.328% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 89.973% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 121.523% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 150.634% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 119.085% |
| TG Therapeutics, Inc. | 12.67 Million USD | 524.108% |
| Blueprint Medicines Corporation | -506.98 Million USD | 89.399% |
| Insmed Incorporated | -749.56 Million USD | 92.83% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 84.736% |
| Incyte Corporation | 597.59 Million USD | 108.993% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 92.933% |